Stocktoria
Vanda Pharmaceuticals Inc. VNDA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2006-04-12
Vanda Pharmaceuticals Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $216.1M | $198.8M | $192.6M | $254.4M | $268.7M |
| R&D expense | $109.3M | $74.4M | $76.8M | $85.8M | $75.4M |
| SG&A expense | $238.0M | $146.4M | $112.9M | $136.5M | $124.0M |
| Operating income | -$151.2M | -$40.7M | -$14.0M | $6.3M | $42.2M |
| Income tax | $81.8M | -$4.0M | $3.8M | $5.0M | $9.2M |
| Net income | -$220.5M | -$18.9M | $2.5M | $6.3M | $33.2M |
| EPS (diluted) | $-3.74 | $-0.33 | $0.04 | $0.11 | $0.58 |
| Operating cash flow | -$109.4M | -$15.8M | $12.8M | $32.0M | $64.2M |
| Free cash flow | -$110.4M | -$16.2M | $12.4M | $31.3M | $63.7M |
| Cash & equivalents | $84.9M | $102.3M | $135.8M | $135.0M | $52.1M |
| Inventory | $1.9M | $1.7M | $1.4M | $1.2M | $1.0M |
| Total assets | $488.9M | $656.2M | $648.4M | $634.2M | $593.8M |
| Total liabilities | $161.8M | $117.7M | $103.5M | $107.0M | $88.9M |
| Shareholders' equity | $327.2M | $538.5M | $544.9M | $527.2M | $504.9M |
Source: SEC EDGAR filings · CIK 0001347178 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.